Inhibikase Therapeutics (IKT) Institutional Ownership $2.97 -0.29 (-8.90%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$2.94 -0.04 (-1.18%) As of 02/21/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Institutional Ownership Changes (13F Filings) for Inhibikase Therapeutics (NYSE:IKT)CurrentInstitutional OwnershipPercentage3.81%Number ofInstitutional Buyers(last 12 months)18TotalInstitutional Inflows(last 12 months)$77.66MNumber ofInstitutional Sellers(last 12 months)0 Get IKT Insider Trade Alerts Want to know when executives and insiders are buying or selling Inhibikase Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data IKT Institutional Buying and Selling by Quarter Inhibikase Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/18/2025 Alpine Global Management LLC14,842$48K0.0%N/A0.021% 2/17/2025 Soleus Capital Management L.P.6,325,000$20.56M1.3%N/A9.119% 2/17/2025 Squarepoint Ops LLC28,411$92K0.0%N/A0.041% 2/17/2025 Stonepine Capital Management LLC1,132,388$3.68M3.0%N/A1.633% 2/17/2025 OMERS ADMINISTRATION Corp54,600$177K0.0%N/A0.079% 2/17/2025 Millennium Management LLC142,209$462K0.0%N/A0.205% 2/17/2025Jefferies Financial Group Inc.14,800$48K0.0%N/A0.021% 2/17/2025 Fairmount Funds Management LLC6,125,000$19.91M2.0%N/A8.831% 2/17/2025 Blackstone Inc.2,070,684$6.73M0.0%N/A2.985% 2/17/2025 Caxton Corp16,393$53K0.3%N/A0.024% Get the Latest News and Ratings for IKT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/14/2025 Nantahala Capital Management LLC2,190,000$7.12M0.3%N/A3.157% 2/14/2025 Northern Trust Corp64,011$208K0.0%N/A0.092% 2/14/2025 Alpine Global Management LLC14,842$48K0.0%N/A0.021% 2/14/2025 Stifel Financial Corp13,129$43K0.0%N/A0.019% 2/13/2025 Barclays PLC84,000$273K0.0%N/A0.121% 2/13/2025 ADAR1 Capital Management LLC5,103,005$16.59M3.3%N/A7.357% 2/12/2025 Geode Capital Management LLC322,878$1.05M0.0%+544.9%0.466% 2/12/2025 Blair William & Co. IL134,953$439K0.0%+7.0%0.195% 8/15/2024 Armistice Capital LLC589,575$713K0.0%N/A8.170% 11/15/2023 Armistice Capital LLC186,046$259K0.0%-62.5%3.477% 9/21/2023 Barclays PLC11,455$41K0.0%N/A0.214% 8/8/2023 Hamilton Lane Advisors LLC13,802$50K0.0%-83.3%0.266% 5/2/2023 Hamilton Lane Advisors LLC82,817$54K0.0%N/A0.286% 2/10/2023 Blair William & Co. IL229,000$114K0.0%+27.9%0.817% 7/12/2022 Koshinski Asset Management Inc.65,377$49K0.0%N/A0.259% 5/6/2022 Retirement Planning Co of New England Inc.116,402$172K0.1%-21.0%0.461% 5/5/2022Lynwood Capital Management Inc.120,000$178K0.2%-52.9%0.476% 5/4/2022 Hamilton Lane Advisors LLC165,635$245K0.1%N/A0.657% 5/3/2022 Redmond Asset Management LLC122,682$182K0.1%N/A0.486% 2/14/2022 Murchinson Ltd.220,947$327K0.0%-31.2%0.878% 2/8/2022 Retirement Planning Co of New England Inc.147,331$216K0.1%N/A0.586% 2/3/2022ACT Capital Management LLC1,076,500$1.58M1.1%+6.6%4.279% 11/16/2021ACT Capital L.L.C.1,010,000$1.92M1.0%+15.4%4.019% 11/16/2021 Warberg Asset Management LLC26,000$49K0.0%-71.1%0.103% 11/9/2021BlackRock Inc.50,741$96K0.0%+273.9%0.202% 8/17/2021Zeke Capital Advisors LLC93,800$263K0.0%+398.9%0.926% 8/16/2021 Antara Capital LP250,000$700K0.0%N/A2.467% 8/16/2021 Warberg Asset Management LLC90,000$252K0.0%N/A0.888% 8/16/2021 Sabby Management LLC421,200$1.18M0.2%N/A4.157% 8/13/2021 Altium Capital Management LP109,749$307K0.1%N/A1.083% Shocking Elon Move: Bigger than DOGE? (Ad)After saving free speech with his acquisition of Twitter… And after blowing everyone’s minds with his recent DOGE moves… What Elon Musk is about to do next could not only shock the world… But also put an extra $30,000 a year in your pocket.Click here to see the details BEFORE March 17th…8/13/2021 Murchinson Ltd.320,947$899K0.3%N/A3.167% 8/13/2021 Vanguard Group Inc.470,615$1.32M0.0%N/A4.644% 8/13/2021 FMR LLC433,300$1.21M0.0%+333.3%4.276% 8/12/2021 Kepos Capital LP700,000$1.96M0.1%N/A6.908% 5/21/2021 Citadel Advisors LLC17,857$107K0.0%N/A0.178% 5/18/2021 Millennium Management LLC11,224$67K0.0%N/A0.112% 5/18/2021 Citadel Advisors LLC17,857$107K0.0%N/A0.178% 5/17/2021 HRT Financial LP11,614$69K0.0%N/A0.115% (Data available from 1/1/2016 forward) IKT Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of IKT shares? During the previous two years, 19 institutional investors and hedge funds held shares of Inhibikase Therapeutics. The most heavily invested institutionals were Soleus Capital Management L.P. ($20.56M), Fairmount Funds Management LLC ($19.91M), ADAR1 Capital Management LLC ($16.59M), Nantahala Capital Management LLC ($7.12M), Blackstone Inc. ($6.73M), Stonepine Capital Management LLC ($3.68M), and Geode Capital Management LLC ($1.05M).Learn more on IKT's institutional investors. What percentage of Inhibikase Therapeutics stock is owned by institutional investors? 3.81% of Inhibikase Therapeutics stock is owned by institutional investors. Learn more on IKT's institutional investor holdings. Which institutional investors have been buying Inhibikase Therapeutics stock? Of the 19 institutional investors that purchased Inhibikase Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Soleus Capital Management L.P. ($6.33M), Fairmount Funds Management LLC ($6.13M), ADAR1 Capital Management LLC ($5.10M), Nantahala Capital Management LLC ($2.19M), Blackstone Inc. ($2.07M), Stonepine Capital Management LLC ($1.13M), and Armistice Capital LLC ($589.58K). How much institutional buying is happening at Inhibikase Therapeutics? Institutional investors have bought a total of 24,358,807 shares in the last 24 months. This purchase volume represents approximately $78.23M in transactions. Which Inhibikase Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Inhibikase Therapeutics stock in the last 24 months: Armistice Capital LLC ($310.50K), and Hamilton Lane Advisors LLC ($69.02K). How much institutional selling is happening at Inhibikase Therapeutics? Institutional investors have sold a total of 379,516 shares in the last 24 months. This volume of shares sold represents approximately $1.93M in transactions. Related Companies DNTH Major Shareholders KURA Major Shareholders LENZ Major Shareholders RLAY Major Shareholders VERV Major Shareholders QURE Major Shareholders ABUS Major Shareholders CRMD Major Shareholders IMTX Major Shareholders TYRA Major Shareholders This page (NYSE:IKT) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
